

Adipose issue-derived stem cells in tissue engineering and cell therapy




Lucie Bačáková¹, Nikola Kročilová¹, Jana Havlíková¹, Martin Pařízek¹, Hooman Motarjemi², Martin Molitor²

¹Dept. Of Biomaterials and Tissue Engineering, Institute of Physiology, Academy of Sciences of the Czech Republic, Vídeňská 1083, Praha 4 – Krč


²Dept. of Plastic Surgery, Bulovka Hospital, Budínova 67/2, Praha 8 – Libeň

Biomaterials and Tissue Engineering

- **A biomaterial** is any matter, surface, or construct that interacts with living systems
 - **Nature-derived** (ECM proteins, polysaccharides...)
 - **Prepared artificially** (metallic alloys, synthetic polymers, ceramics, composite materials...)
- Biomaterials are used as cell carriers for **tissue engineering (TE)**
 - an interdisciplinary field that applies the principles of engineering and the life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function (Langer and Vacanti, Science 260: 920-926, 1993)




Basic principles of Tissue engineering



Definition of Stem Cells

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells.



Mike Jones: The source of pluripotent stem cells from developing embryos.

https://commons.wikimedia.org/wiki/File:Stem_cells_diagram.png#/media/File:Stem_cells_diagram.png

Sources of Stem Cells

- **Embryonic**

- Zygote
- Morula
- Blastula
- Blastocyst

- **Adult organism**

- Bone marrow
- Blood (endothelial progenitor cells)
- Skeletal muscle satellite cells
- Skin
- Organs (liver, heart, kidneys...)
- Urinary stem cells
- **Adipose tissue-derived stem cells**

- **Extrafetal tissues**

- Placenta
- Amniotic fluid
- Umbilical cord
- Umbilical cord blood

- **Induced pluripotent stem cells (iPS)**

- Genetically manipulated and reprogrammed from adult differentiated somatic cells
- Potential tumorigenicity
- Immunogenicity

Why Stem Cells?

- Non-differentiated cells with a **higher proliferation potential** than in differentiated cells
- Can be isolated in **larger quantities**
- Expandable to **larger quantities**, withstand **more passages**, **slower senescence**
- **Less immunogenic** than differentiated cells
- **Immunomodulatory** and **immunosuppressive** function (treatment of inflammatory and autoimmune diseases)
- Have **autocrine and paracrine** functions
- Can be **differentiated** into desired cell phenotypes by appropriate culture conditions

Adipose Tissue-Derived Stem Cells (ASCs)

- Seem to be **the most advantageous** for cell therapies and tissue engineering
- Adipose tissue is **abundant** in many patients
- Subcutaneous localization, **easily accessible**
- Can be easily harvested with **less discomfort, low donor-site morbidity** and **high amount** compared to bone marrow-derived stem cells
- **High amount of ASCs:**
 - adipose tissue: is 1 cell per 50 cells
 - bone marrow: 1 cell per 10 000 cells
- **Higher proliferation capacity** compared to bone marrow stem cells (BMSCs)
- Undergo **senescence later** than BMSCs
- **No calcification** when used for cardiovascular tissue engineering

Clinical Applications of ASCs I

- **Cell-assisted lipotransfer for tissue augmentation**

(CAL): autologous ASCs implanted together with an autologous fat graft in order to enhance its survival and to reduce its postoperative atrophy or resorption

- **cosmetic breast enhancement**
- **facial contouring** - Parry-Romberg syndrome (progressive atrophy of the right hemiface)



A. Preoperative view of a 19 year old woman with Parry-Romberg Syndrome.

B. Postoperative view of a 19 year old woman, one year after Cell Assisted Lipotransfer.

Clinical Applications of ASC II

- **Local injection of ASCs**
 - healing wound after radiation therapy
 - skin rejuvenation
- **Treatment of inflammatory and autoimmune diseases**
(by intravenous infusion of stem cells):
 - graft-versus-host disease
 - Crohn's disease
 - multiple sclerosis
- **Orthopaedic applications**
 - **Repair of maxilla:** ASCs + β -tricalcium phosphate and bone morphogenetic protein-2 (Mesimaki K *et al.*: Int J Oral Maxillofac Surg 2009;38:201–9)
 - **Repair of calvaria:** ASCs + fibrin glue in a 7-year-old girl with severe head injury (Lendeckel S *et al.*: J Craniomaxillofac Surg 2004;32:370–3)

Clinical Applications of ASC III

- Critical limb ischemia – „diabetic foot“

Patient 7

Patient 3

Patient 1

Day 0



Day 180



- ASCs from abdominal fat were grown for 2 weeks
- More than 200 million cells were obtained
- ASCs (10^8) were then intramuscularly injected into the ischemic leg of patients



Bura A *et al.*:
Cytotherapy 16(2):
245-257, 2014.

Paracrine Function of Stem Cells

- **Able to produce various growth factors:**
 - vascular endothelial growth factor (VEGF)
 - basic fibroblast growth factor (bFGF)
 - epidermal growth factor (EGF)
 - keratinocyte growth factor (KGF)
 - platelet-derived growth factor (PDGF)
 - hepatocyte growth factor (HGF)
 - transforming growth factor-beta (TGF- β)
 - insulin-like growth factor (IGF)
 - brain-derived neurotrophic factor (BDNF)
- **Antioxidative effects**
- **Stem cells improve the growth and function of cells in the damaged tissues by paracrine manner**

Isolation of Adipose Stem Cells


- Fat tissue obtained by **liposuction** (Dept. of Plastic Surgery, Bulovka Hospital, Prague), 10 ml of lipoaspirate
- **Rinsed** repeatedly with phosphate-buffered saline in order to remove blood cells
- **Digested** by collagenase I (1 hour at 37°C, shaking), centrifuged
- **Filtered** through Cell Strainer (100 μm pores, BD Falcon, U.S.A.)
- **Seeded** into polystyrene flasks (25 cm^2 , TPP, Switzerland; 0.16 ml of the original lipoaspirate per cm^2)




Estes BT *et al.*:
Nat Protoc 5:
1294-1311,
2010

Characterization of ASCs by Flow Cytometry


CD 105 (Endoglin, part of TGF beta receptor complex)




CD 73 (ecto-5'-nucleotidase, converts AMP to adenosine)




CD 29 (Integrin beta-1, fibronectin receptor)




CD 146 (Melanoma cell adhesion molecule, receptor for laminin alpha 4)





CD 90 (immunoglobuline Thy-1)



CD 34 (Hematopoietic progenitor cell antigen)



CD 31 (Platelet endothelial cell adhesion molecule, PECAM-1)



Differentiation of ASCs

- **Relatively easy:**

- Adipocytes
- Osteoblasts
- Vascular smooth muscle cells

- **Difficult:**

- Endothelial cells
- Keratinocytes


- **Methods of differentiation:**

- Composition of cell culture medium
- Appropriate scaffolds
- Mechanical stimulation in dynamic cell culture systems
- Electrical stimulation


Adipogenic Differentiation

- Cultivation in DMEM medium (with FCS) supplemented with:
 - Dexamethasone (1 mM)
 - 3-isobutyl-1-methylxanthine (0.5 mM)
 - Indomethacin (60 mM)
 - Insulin (10 mg/ml)
 - Hydrocortisone (0.5 mM)
- Oil Red O (lipids stained in red):

Cells in standard medium




Cells in adipogenic medium




Osteogenic Differentiation

- **Cultivation in DMEM medium (with 10% of FCS) supplemented with:**
 - Dexamethasone 10^{-8} M (393 ng/ml)
 - β -glycerolphosphate..... 10 mM (2.16 mg/ml)
 - L-glutamine 2 mM (292 μ g/ml)
 - Ascorbic acid..... 50 μ g/ml
 - Dihydroxyvitamin D₃..... 10^{-6} M (385 ng/ml)
- **Alizarin Red (mineral deposits stained in red):**

Cells in standard medium



Cells in osteogenic medium



Influence of Liposuction Parameters on the Quantity and Quality of ASCs

- Manual liposuction or vacuum machine
- Anaesthesia (general, local)
- Composition of tumescent solution:
 - Isotonic NaCl
 - Lidocain (2%): anaesthesia, emulsification of fat tissue
 - Adrenalin (1:200000): in order to stop bleeding


- Negative pressure:

- 200 mm Hg
- 700 mm Hg
- Taken from the same patient
(left and right parts of the abdomen)






Patient 1: Day 1 after isolation – before medium change

Low negative pressure (-200 mmHg)





High negative pressure (-700 mmHg)





Patient 1: Primoculture, day 5 after isolation

Low negative pressure (-200 mmHg)



$39\,800 \pm 3\,600$ cells/cm²



High negative pressure (-700 mmHg)





$62\,900 \pm 3\,100$ cells/cm²

Patient 1: Passage 1 (4 000 cells/cm²)

Low negative pressure (-200 mmHg) High negative pressure (-700 mmHg)



Day 2



Day 4


18 500 ± 600 cells/cm²

27 900 ± 2 600 cells/cm²


Patient 1: Passage 2 (4 000 cells/cm²)

Low negative pressure (-200 mmHg)

High negative pressure (-700 mmHg)





8 300 ± 400 cells/cm²



13 000 ± 600 cells/cm²

Day 3





Day 7



Patient 2 - Primoculture

Low negative pressure (-200 mmHg)

High negative pressure (-700 mmHg)



Primoculture
day 1




Primoculture
day 6

Osteogenic Cell Differentiation


Measured by the intensity of fluorescence after immunofluorescence staining of collagen I, alkaline phosphatase and osteocalcin

Pat. 1, pas. 2, low pressure, after freezing, day 5



Standard medium



Osteogenic medium






- Fluorescent Image Analyser software (version 1.0)
- The fluorescence intensity was normalized per cell
- The fluorescence intensity of control samples stained without primary antibodies was subtracted



Matejka, R., ALICE:
Fluorescent Image Analyser
(ver 1.0);
<http://alice.fbmi.cvut.cz>


Osteogenic Differentiation (pat. 1, pas. 2, after freezing, d. 5)



Flow-cytometric characterization of ASCs


black: ASC-H – control/ **blue:** ASC-L – control/ **red:** ASC-H - stained/ **yellow:** ASC-L -stained

CD105 (endoglin, part of TGF- β receptor complex)




ASC-H: 88 %
ASC-L: 70 %

CD90 (immunoglobuline Thy-1)




ASC-H: 100 %
ASC-L: 90 %

CD73 (ecto-5'-nucleotidase)




ASC-H: 100 %
ASC-L: 99 %

CD29 (integrin β_1 , fibronectin receptor)




ASC-H: 100 %
ASC-L: 60 %

CD34 (hematopoietic progenitor cell antigen)




Not detected

CD31 (platelet-endothelial cell adhesion molecule, PECAM-1)




Not detected

CD45 (member of the protein tyrosine phosphatase family)



Not detected

CD146 (melanoma cell adhesion molecule, receptor for laminin α_4)



Not detected

Conclusion

Parameter	Lower pressure (-200 mm Hg)	Higher pressure (-700 mm Hg)
Amount of adhering ASCs after isolation	↓	↑
Growth of ASCs (measured by cell number)	↓	↑
Osteogenic differentiation of ASCs (AF, Ocn)	↑	↓

These differences could be, at least partly, explained by phenotypic differences between the two ASC populations revealed by flow cytometry

Supported by the grant „ Application of adipose tissue-derived stem cells obtained by liposuction in tissue engineering“, No. 15-33018A, Ministry of Health of the CR

Team members:



Roman Matějka

Petr Slepíčka

Václav Švorčík

Martin Molitor

Alexander Kromka

Štěpán Potocký



Jana Havlíková

Zdeňka Kolská

Nikola Kročilová

Hooman Motarjemi

Thank you very much for your attention!




Cell Staining & Microscopy




Cell Number (patient 1, pas. 2, after freezing, day 5)


Cell number (Vi-CELL Analyser, day 5)



Cell number (microphotographs, day 5)




Cell number (ImageJ, day 5)




Osteogenic Differentiation (pat. 1, pas. 2, after freezing, d. 12)


Kolagen (12. den)



Alkalická fosfatáza (12. den)



Osteokalcin (12. den)



Ti-6Al-4V Alloy with Various Surface Modifications

Prepared in collaboration with VUHZ Joint-Stock Co. (Dr. Roman Gabor) and Medin Joint-Stock Co. (Dr. Jaroslav Marvan)





K Control unmodified samples (disc, diameter 14 mm, thickness 2 mm, $R_a = 280$ nm)

A Modified by shot blasting and tarnishing (tryskání a matování), $R_a = 200$ nm





B Vibratory finishing (omílání), $R_a = 100$ nm

C Vibratory finishing, shot blasting and polishing (omílání, tryskání a leštění), $R_a = 80$ nm

SEM



AFM




Contact Angle and Surface Free Energy

Sample	Contact angle [°]		Surface free energy [mN/m]		
	Water	Polyethylene glycol	Total	Disperse part	Polar part
K	85.6 ± 4.9	63.4 ± 4.1	25.4 ± 13.85	19.5 ± 8.47	6 ± 5.38
A	56.8 ± 2.1	12.4 ± 2.9	50.9 ± 2.72	45.3 ± 1.8	5.7 ± 0.9
B	52.7 ± 4.7	33.0 ± 0.7	47.0 ± 10.98	12.8 ± 3.42	34.2 ± 7.55
C	44.0 ± 2.3	30.4 ± 3.0	55.4 ± 5.97	8.7 ± 1.75	46.7 ± 4.22


Mean ± S.D. from 7 measurements (Inst. Chemical Technology; Dr. Nikola Kasálková Slepíčková)

Cell Number on Ti-6Al-4V samples


A. ASC-L cells, day 3




D. ASC-L cells, day 7




B. ASC-H cells, day 3




E. ASC-H cells, day 7



C. MG-63 cells, day 3



F. MG-63 cells, day 7



Mean \pm S.E.M.
from 20
measurements

ANOVA, Student-
Newman-Keuls
method.

$p \leq 0.05$
compared to the
groups mentioned
above the
columns.

Cell Morphology on Ti-6Al-4V Samples




MG-63 cells

ASCs - low

ASCs - high




Day 7 after seeding

K






Control non-modified

A






Shot blasting and
tarnishing (tryskání a
matování)

B



Vibratory finishing (omílání)

C



Vibratory finishing, shot
blasting and polishing
(omílání, tryskání a leštění)

Texas Red C₂-Maleimide and Hoechst 33258. Olympus IX 51 microscope, DP 71 digital camera, objective 10x, bar = 200 μm